

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-86)

TIBULIZUMAB

PRONUNCIATION

tye" bue liz' ue mab

THERAPEUTIC CLAIM

Treatment of autoimmune disorders

CHEMICAL NAMES

1. Immunoglobulin, bispecific tetravalent, anti-(human B-cell activating factor of the tumor necrosis factor family/human interleukin 17) heavy chain, disulfide with anti-(B-cell activating factor of the tumor necrosis factor family) light chain, dimer
2. Immunoglobulin G4-kappa, bispecific tetravalent, anti-(human tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator, BlyS, B-cell-activating factor, BAFF, CD257 antigen)) / anti-(human interleukin-17A (IL-17A, cytotoxic T-lymphocyte-associated antigen 8, CTLA-8)), humanized monoclonal antibody; γ 4 heavy chain (1-448) [human VH (*Homo sapiens* IGHV4-34*01–(IGHD)-IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01{hinge S¹⁰>P(231), CH3 L¹⁰⁵>P(448), G¹⁰⁶>del, K¹⁰⁷>del} (124-448)] fusion protein with tetraglycyl-L-seryltetraglycyl-L-threonyltetraglycyl-L-seryl-[humanized VH (*Homo sapiens* IGHV1-69*01 (84%) –(IGHD)-IGHJ4*01) [8.8.12] (464-582)] fusion protein with tetrakis(tetraglycyl-L-seryl)-[humanized V-KAPPA (*Homo sapiens* IGHV2D-29*02 (89%) –(IGHD)-IGKJ2*02) (91%) [11.3.9] (603-714)] (137-214')-disulfide with κ light chain (1'-214') [human V-KAPPA (*Homo sapiens* IGKV3-11*01 (98%) –IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (229-229':232-232'')-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

QQQLQQWGAG	LLKPSETLSL	TCAVYGGSF	GYYSWIRQP	PGKLEWIGE	50
INHSGSTNYN	PSLKSRTVIS	VDTSKNQFSL	KLSSVTAADT	AVYYCARGYY	100
DILTGYYYYF	DYWGQGLVLT	VSSASTKGPS	VFPLAPCSRS	TSESTAALGC	150
LVKDYFPEPV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200
TKTYTCNVDH	KPSNTRVDKR	VESKYGPPCP	PCPAPEFLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCTVVVDVS	QEDPEVQFNW	YVDGVEVHNA	KTKPREEQFN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKG	LPSSIEKTIS	KAKGQPREPQ	350
VYTLPPSQEE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSDGSFPLY	SRLTVDKSRW	QEGNVFSCSV	MHEALHNHYT	QKSLSLSPGG	450
GGSGGGGTGG	GGSQQLVQS	GAEVKKGSS	VKVSCASGY	KFTDYHIHWV	500
RQAPGQCLEW	MGVINPTYGT	TDYNQRFKGR	VTITADESTS	TAYMELSSLR	550
SEDTAVYYCA	RYDYFTGTGV	YWGQGLVTV	SSGGGGSGGG	GSGGGSGGG	600
GSDIVMTQTP	LSLSVTPGQP	ASISCRSSRS	LVHSRGETYL	HWYLQKPGQS	650
PQLLIYKVSN	RFIGVDRFS	GSGSGTDFTL	KISRVEADV	GVYYCSQSTH	700
LPFTFGCGTK	LEIK				714

Light chain

EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	RYLAWYQQKP	GQAPRLLIYD	50'
ASNRATGIPA	RFSGSGSGTD	STLTLSSELP	EDFAVYYCQQ	RSNWPRTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSNTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-95	22"-95"	23'-88'	23"-88"	134'-194'	134"-194"	137-214'	
137"-214"	150-206	150"-206"	229-229"	232-232"	264-324	264"-324"	
370-428	370"-428"	485-559	485"-559"	507-707	507"-707"	625-695	625"-695"

Glycosylation sites (N)

Asn-300 Asn-300"

MOLECULAR FORMULA $C_{8934}H_{13698}N_{2398}O_{2808}S_{56}$ (non-glycosylated)

MOLECULAR WEIGHT 201.4 kDa (non-glycosylated)

TRADEMARK None as yet

SPONSOR Eli Lilly & Company

CODE DESIGNATIONS LY 3090106

CAS REGISTRY NUMBER 1849636-24-3

UNII 42HQ15W1ZF

WHO NUMBER 10656

gbk